Julie Graff, MD, shares her insight on pivotal trials exploring abiraterone acetate (Zytiga) and docetaxel in this in patients with castration-sensitive prostate cancer.
Original Article: Expert Addresses Abiraterone Versus Docetaxel in Castration-Sensitive Prostate Cancer